February 01, 2023
Peter Marks, MD, PhD, director of FDA’s Center for Biologics Evaluation and Research, will join an AABB Hot Topic Discussion from 2-3 p.m. ET on Thursday to discuss FDA’s recent draft guidance on individual risk assessment.
Following Marks’ presentation, Sharon Carayiannis, MT(ASCP)HP, AABB’s vice president of science and practice, will moderate a question-and-answer session. AABB is accepting questions from the community until 2 p.m. ET today.
Registration is complimentary but required.